Evogene announced a new phase of its partnership with Google Cloud that will embed advanced AI agents into its ChemPass AI platform, leveraging Vertex AI to automate and scale discovery workflows for small‑molecule candidates.
The expansion builds on the October 2024 collaboration that delivered a generative AI foundation model trained on 40 billion molecular structures, and it positions Evogene to accelerate the design‑make‑test‑analyze cycle for pharmaceutical partners.
By integrating autonomous agents, Evogene aims to increase the precision and throughput of its molecule‑design engine, enabling faster validation of drug leads and allowing multiple discovery programs to run in parallel.
CEO Ofer Haviv said the move marks a shift from AI models to autonomous discovery, stating that the new agents will improve speed, cost structure, and the ability to scale complex workflows across the company’s portfolio.
Managing Director Boaz Maoz of Google Cloud Israel highlighted that the partnership will help accelerate the identification of small molecules and demonstrate the power of combining cutting‑edge AI with scientific research.
The collaboration is part of Evogene’s broader strategy to become a pure‑play pharma AI company, a shift that could attract larger pharmaceutical collaborations and strengthen its competitive position against well‑funded rivals in the life‑science AI market.
Investors welcomed the announcement, noting that the expanded partnership could unlock new revenue streams and enhance Evogene’s value proposition in both pharmaceutical and agricultural sectors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.